The full scope at Ascend includes: Obesity and overweight with comorbidities - full workup, GLP-1 candidacy assessment, lifestyle integration Type 2 diabetes with weight management goals - GLP-1 medications often address both indications simultaneously Hypertension tied to weight - coordinated medication review and lifestyle work Dyslipidemia and metabolic syndrome - lipids often improve markedly with weight loss Prediabetes - HbA1c 5.7-6.4% range, where intervention can prevent progression Fatty liver disease (MASLD) - weight loss is the primary intervention
A gentle 10-minute walk can encourage digestive motility and reduce the feeling of heaviness in the stomach
Whatever your reason, the market has expanded rapidly and there are strong options at every price point
Back GBD 2019 Risk Factor Collaborators (2020) 'Global Burden of 87 Risk Factors in 204 Countries and Territories, 19902019: a systematic analysis for the global burden of disease study 2019', The Lancet , 396, 122349
Packaging Quality & Security Minor issues Heres where things got sloppy
However, restarting often requires rebuilding tolerance to the medication, which may include an adjustment period similar to your initial treatment
